Small cell lung cancer

37 trials 15 recruiting MedDRA PT
37 Registered trials
15 Recruiting
28 Unique sponsors
31 Unique IMPs
35 Commercial trials
Drug classes (ATC)
— ATC code not specified 28
L Oncology (ATC L) 9
Mechanism of action (INN-stem analysis)
Unknown / small molecule 17 substances
Checkpoint inhibitor (PD-L1) 2 substances
Checkpoint inhibitor (CTLA-4) 2 substances
Checkpoint inhibitor (PD-1) 2 substances
Monoclonal antibody (rat) 1 substance
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody (human) 1 substance
Monoclonal antibody (immune) 1 substance
Kinase inhibitor 1 substance
SERD 1 substance
CDK inhibitor 1 substance
PARP inhibitor 1 substance
Phase III: 7 Phase II: 10 Phase I/II: 4 Phase I: 9 Phase I (Other): 5 Phase I (First in Human): 2

Filter these 37 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 37 trials

Phase III

7 trials
  • Astrazeneca Farmaceutica Spain S.A. Commercial
    DURVALUMAB
    2025-521340-37-00 1 country 2025 n=70
    Recruiting
  • BioNTech SE Commercial
    ATEZOLIZUMAB; BNT327
    2024-515765-34-00 7 countries 2026 n=249
    Recruiting
  • Daiichi Sankyo Inc. Commercial
    IFINATAMAB DERUXTECAN
    2023-509628-16-00 13 countries 2026 n=272 Orphan
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    ATEZOLIZUMAB; TIRAGOLUMAB
    2022-502988-37-00 3 countries 2020 n=90
    Ended
  • Pharma Mar S.A. Commercial
    LURBINECTEDIN
    2024-513559-34-00 11 countries 2022 n=517 Orphan
    Ended
  • Shanghai Henlius Biotech Inc. Commercial
    SERPLULIMAB
    2024-515047-31-00 9 countries 2023 n=111 Orphan
    Ended
  • Zai Lab (US) LLC Commercial
    ZL-1310
    2025-522818-23-00 11 countries n=234
    Pending

Phase II

10 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST SEZ6, CONJUGATED TO (2S)-2-(2-BROMOACETAMIDO)-N-[(2S)-1-({3-[(7S)-7-ETHYL-7-HYDROXY-8,11-DIOXO-7,8,11,13-TETRAHYDRO-2H,10H-[1,3]DIOXOLO[4,5-G]PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-14-YL]BICYCLO[1.1.1]PENTAN-1-YL}AMINO)-1-OXOPROPAN-2-YL]-3-METHYLBUTANAMIDE
    2024-517490-24-00 5 countries 2026 n=60
    Recruiting
  • Advenchen Pharmaceuticals LLC Commercial
    AL8326
    2023-509067-24-00 2 countries n=30
    Not authorised
  • Advenchen Pharmaceuticals LLC Commercial
    AL8326
    2023-509067-24-01 2 countries 2025 n=50
    Ended
  • Amgen Inc. Commercial
    TARLATAMAB
    2024-516051-40-00 6 countries 2025 n=92 Orphan
    Ended
  • Boehringer Ingelheim International GmbH Commercial
    BI 764532; IGG-LIKE T CELL ENGAGER BINDING TO DLL3 AND CD3
    2023-504247-13-00 8 countries 2023 n=122 Orphan
    Recruiting
  • Evergreen Theragnostics Inc. Commercial
    GALLIUM (68GA), EVG321
    2024-514584-25-00 3 countries 2024 n=23
    Recruiting
  • Owlstone Medical Limited Commercial
    D5-ETHYL-BETA-D-GLUCURONIDE
    2023-503574-20-00 2 countries 2023 n=100
    Ended
  • Pfizer Inc. Commercial
    PF-08634404
    2025-524686-24-00 3 countries n=15
    Pending
  • ETOP IBCSG Partners Foundation Academic
    ATEZOLIZUMAB; DURVALUMAB; NIRAPARIB TOSILATE MONOHYDRATE
    2022-502092-33-00 5 countries 2024 n=35 Orphan
    Recruiting
  • ETOP IBCSG Partners Foundation Academic
    TARLATAMAB
    2025-522288-13-00 4 countries 2026 n=40
    Recruiting

Phase I/II

4 trials
  • Bristol Myers Squibb International Corporation Commercial
    IPILIMUMAB; NIVOLUMAB
    2024-516540-25-00 1 country 2013 n=83
    Ended
  • Cyclacel Limited Commercial
    CYC140 MONOHYDROCHLORIDE MONOHYDRATE
    2024-516290-67-00 1 country 2022 n=56
    Ended
  • Merck Sharp & Dohme LLC Commercial
    GOCATAMIG; IFINATAMAB DERUXTECAN
    2024-517926-25-00 1 country 2025 n=65
    Recruiting
  • Pfizer Inc. Commercial
    [(1R,3S)-3-[3-[[5-(METHOXYMETHYL)-2-METHYLPYRAZOLE-3-CARBONYL]AMINO]-1H-PYRAZOL-5-YL]CYCLOPENTYL]N-PROPAN-2-YLCARBAMATE MONOHYDRATE; FULVESTRANT; LETROZOLE; PALBOCICLIB
    2024-515492-34-00 1 country 2023 n=12
    Ended

Phase I

9 trials
  • Beigene Ltd. Commercial
    IMP not specified
    2023-503996-38-00 1 country 2025 n=60
    Ended
  • Beigene Ltd. Commercial
    IMP not specified
    2023-505322-34-00 1 country 2024 n=45
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2025-523165-19-00 1 country 2026 n=15
    Recruiting
  • Evergreen Theragnostics Inc. Commercial
    IMP not specified
    2024-518039-12-00 2 countries 2025 n=20
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2023-506354-20-00 5 countries 2024 n=36
    Ended
  • Fusion Pharmaceuticals Inc. Commercial
    IMP not specified
    2025-521235-37-00 1 country n=45
    Ended
  • Immunocore Limited Commercial
    IMP not specified
    2023-509767-25-00 3 countries 2024 n=520
    Recruiting
  • Seagen Inc. Commercial
    IMP not specified
    2023-505858-18-00 4 countries 2024 n=175
    Halted
  • Zai Lab (US) LLC Commercial
    IMP not specified
    2024-514446-36-00 1 country 2024 n=80
    Recruiting

Phase I (Other)

5 trials
  • AstraZeneca AB Commercial
    DURVALUMAB; DURVALUMAB, HYALURONIDASE (HUMAN RECOMBINANT); TREMELIMUMAB
    2025-521639-34-00 1 country 2026 n=4
    Recruiting
  • Celgene Corp. Commercial
    IMP not specified
    2023-509800-14-00 2 countries 2019 n=66
    Ended
  • Debiopharm International S.A. Commercial
    IMP not specified
    2024-510980-40-00 1 country 2023 n=50
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2023-508371-36-00 1 country 2024 n=6
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2024-516907-18-00 1 country 2024 n=16
    Ended

Phase I (First in Human)

2 trials
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    BMS-986525; NIVOLUMAB
    2025-524090-16-00 3 countries 2026 n=21
    Recruiting
  • Salubris Biotherapeutics Inc. Commercial
    JK08; LENVATINIB; PEMBROLIZUMAB
    2024-511750-53-00 2 countries 2022 n=130
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 4 Phase I (Other), Phase II, Phase I/II 0
Beigene Ltd. Commercial 2 Phase I 0
Evergreen Theragnostics Inc. Commercial 2 Phase I, Phase II 2
F. Hoffmann-La Roche AG Commercial 2 Phase I, Phase III 0
Zai Lab (US) LLC Commercial 2 Phase I, Phase III 1
Advenchen Pharmaceuticals LLC Commercial 2 Phase II 0
ETOP IBCSG Partners Foundation Academic 2 Phase II 2
BeOne Medicines AG Commercial 1 Phase I 1
Fusion Pharmaceuticals Inc. Commercial 1 Phase I 0
Immunocore Limited Commercial 1 Phase I 1
Seagen Inc. Commercial 1 Phase I 0
AstraZeneca AB Commercial 1 Phase I (Other) 1
Celgene Corp. Commercial 1 Phase I (Other) 0
Debiopharm International S.A. Commercial 1 Phase I (Other) 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase II 1
Amgen Inc. Commercial 1 Phase II 0
Boehringer Ingelheim International GmbH Commercial 1 Phase II 1
Owlstone Medical Limited Commercial 1 Phase II 0
Astrazeneca Farmaceutica Spain S.A. Commercial 1 Phase III 1
BioNTech SE Commercial 1 Phase III 1
New trials by year
2019
1
2020
1
2022
3
2023
5
2024
9
2025
6
2026
7
← All indication landscapes